Patents by Inventor Fabiana Fernandez

Fabiana Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
    Patent number: 11944675
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 2, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
  • Methods of Host Cell Modification
    Publication number: 20220186196
    Abstract: Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 16, 2022
    Inventors: Michael WACKER, Michael KOWARIK, Fabiana FERNANDEZ
  • Methods of host cell modification
    Patent number: 11220676
    Abstract: Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: January 11, 2022
    Inventors: Michael Wacker, Michael Kowarik, Fabiana Fernandez
  • Bioconjugates Made From Recombinant N-Glycosylated Proteins From Procaryotic Cells
    Publication number: 20210085772
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.
    Type: Application
    Filed: October 2, 2020
    Publication date: March 25, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Fabiana FERNANDEZ, Michael KOWARIK, Michael WACKER, Michael WETTER
  • Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
    Patent number: 10835592
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 17, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • METHODS OF HOST CELL MODIFICATION
    Publication number: 20190218561
    Abstract: Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 18, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Michael WACKER, Michael KOWARIK, Fabiana FERNANDEZ
  • Methods of Host Cell Modification
    Publication number: 20170121691
    Abstract: Described herein are methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Application
    Filed: October 13, 2014
    Publication date: May 4, 2017
    Inventors: Michael WACKER, Michael KOWARIK, Fabiana FERNANDEZ
  • METHODS OF HOST CELL MODIFICATION
    Publication number: 20150267207
    Abstract: Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 24, 2015
    Applicant: GLYCOVAXYN AG
    Inventors: Michael Wacker, Michael Kowarik, Fabiana Fernandez
  • BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS
    Publication number: 20150044254
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Applicant: GLYCOVAXYN AG
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
    Patent number: 8895014
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: November 25, 2014
    Assignee: Glycovaxyn AG
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS
    Publication number: 20110097357
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Application
    Filed: February 19, 2009
    Publication date: April 28, 2011
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker